Breaking News Instant updates and real-time market news.

DCPH

Deciphera

$19.91

-3.57 (-15.20%)

07:12
08/13/19
08/13
07:12
08/13/19
07:12

Deciphera announces top-line results from Phase 3 INVICTUS study

Deciphera announced top-line data from the INVICTUS pivotal Phase 3 clinical study of ripretinib, a broad-spectrum KIT and PDGFRa inhibitor, in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors, or GIST. The INVICTUS Phase 3 clinical study is a randomized, double-blind, placebo-controlled, international, multicenter study to evaluate the safety, tolerability and efficacy of ripretinib compared to placebo in 129 patients with advanced GIST whose previous therapies have included at least imatinib, sunitinib, and regorafenib. The INVICTUS study achieved its primary endpoint of improved PFS as determined by blinded independent central radiologic review using modified Response Evaluation Criteria in Solid Tumors, or RECIST, version 1.1. In the INVICTUS study, ripretinib demonstrated a median PFS of 6.3 months compared to one month in the placebo arm and significantly reduced the risk of disease progression or death by 85% compared to placebo. For the key secondary endpoint of objective response rate, or ORR, as determined by blinded independent central radiologic review using modified RECIST version 1.1, ripretinib demonstrated an ORR of 9.4% compared with 0% for placebo, which was not statistically significant. Ripretinib in this study also showed a clinically meaningful improvement over placebo in terms of the secondary endpoint overall survival, or OS. Since statistical significance was not achieved for ORR, the hypothesis testing of OS was not formally performed. According to the pre-specified hierarchical testing procedure of the endpoints, the hypothesis testing of OS cannot be formally conducted unless the test of ORR is statistically significant. The OS data for the placebo arm includes patients taking placebo who, following progression, were crossed-over to ripretinib treatment. Ripretinib was generally well tolerated and the adverse event results in INVICTUS were consistent with data from previously presented Phase 1 study results. Grade 3 or 4 treatment-emergent adverse events, or TEAEs, occurred in 42 patients on the ripretinib arm compared to 19 on the placebo arm. Grade 3 or 4 TEAEs greater than 5% of patients in the ripretinib arm were anemia, abdominal pain and hypertension. Grade 3 or 4 TEAEs greater than 5% of patients in the placebo arm were anemia. Based on the INVICTUS data, the company expects to submit a new drug application, or NDA to the FDA for ripretinib for the treatment of patients with advanced GIST who have received prior treatment with imatinib, sunitinib and regorafenib in Q1 of 2020.

DCPH Deciphera
$19.91

-3.57 (-15.20%)

03/14/19
PIPR
03/14/19
NO CHANGE
Target $50
PIPR
Overweight
Deciphera development of ripretinib 'progressing nicely', says Piper Jaffray
Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $50 price target on Deciphera after its in-line Q4 results, saying the company's development of ripretinib is progressing nicely with ongoing phase 3 enrollment in INTRIGUE study and results for INVICTUS study expected later this year. The analyst remains positive on the shares given the company's "catalyst-rich" second half of the year on tap.
06/03/19
PIPR
06/03/19
NO CHANGE
Target $55
PIPR
Overweight
Deciphera price target raised to $55 from $50 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond raised his price target for Deciphera Pharmaceuticals (DCPH) to $55 from $50 after hosting investor meetings with management and reviewing competitor Blueprint Medicines' (BPMC) avapritinib update over the weekend. Given the "significant" valuation-gap between the two companies, driven by misperceptions around their respective KIT inhibitors, new money investment into Deciphera "right here makes a lot of sense," Raymond tells investors in a research note. He keeps an Overweight rating on the shares.
06/10/19
PIPR
06/10/19
NO CHANGE
Target $55
PIPR
Overweight
Piper Jaffray says a buyer of Deciphera after DCC-3116 added to pipeline
Piper Jaffray analyst Christopher Raymond maintained an Overweight rating and $55 price target on Deciphera following the disclosure of the company's newest preclinical candidate, DCC-3116, an ULK kinase inhibitor important in autophagy initiation. In a research note to investors, Raymond says that given recent advances in KRAS targeting, this target's complementary effects make it an "intriguing" combination agent with the myriad agents approved and in development, adding that he remains a buyer.
07/18/19
DBAB
07/18/19
INITIATION
Target $42
DBAB
Buy
Deciphera initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Konstantinos Aprilakis started Deciphera with a Buy rating and $42 price target. The analyst initiated coverage on eight smid-cap Biotechnology stocks in the oncology space.

TODAY'S FREE FLY STORIES

13:45
08/21/19
08/21
13:45
08/21/19
13:45
General news
Breaking General news story  »

FOMC Minutes to be…

AFL

Aflac

$49.66

-2.2 (-4.24%)

13:38
08/21/19
08/21
13:38
08/21/19
13:38
Periodicals
Aflac reiterates review being done of Post channel sales, Bloomberg says »

Aflac reiterated that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,823.96

21.88 (1.21%)

, WMT

Walmart

$112.15

0.03 (0.03%)

13:37
08/21/19
08/21
13:37
08/21/19
13:37
Periodicals
Amazon opens 'largest campus yet' in south Indian city, Bloomberg says »

According to an earlier…

AMZN

Amazon.com

$1,823.96

21.88 (1.21%)

WMT

Walmart

$112.15

0.03 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 25

    Sep

  • 27

    Oct

  • 13

    Nov

  • 14

    Nov

CBL

CBL & Associates

$0.86

0.022 (2.62%)

13:32
08/21/19
08/21
13:32
08/21/19
13:32
Hot Stocks
CBL Properties to pursue measures to cure NYSE rule non-compliance »

CBL Properties announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
08/21/19
08/21
13:25
08/21/19
13:25
Conference/Events
The Food & Drug Law Institute to hold a webinar »

Anthony Anscombe, Partner…

13:25
08/21/19
08/21
13:25
08/21/19
13:25
Conference/Events
FOMC releases minutes from July 30-31, 2019 Policy Meeting »

The Federal Open Market…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
08/21/19
08/21
13:17
08/21/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,195.07

11.64 (0.98%)

, GOOGL

Alphabet Class A

$1,196.08

11.82 (1.00%)

13:16
08/21/19
08/21
13:16
08/21/19
13:16
Hot Stocks
YouTube Premium users can now listen directly within Waze app »

In an earlier blog post,…

GOOG

Alphabet

$1,195.07

11.64 (0.98%)

GOOGL

Alphabet Class A

$1,196.08

11.82 (1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Oct

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
08/21/19
08/21
13:16
08/21/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHC

Bausch Health

$22.31

1.05 (4.94%)

13:06
08/21/19
08/21
13:06
08/21/19
13:06
Hot Stocks
Bausch Health trades up after VP Humphries buys over $650K in shares »

Bausch Health VP William…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 23

    Sep

FB

Facebook

$185.03

1.27 (0.69%)

, TWTR

Twitter

$42.65

0.355 (0.84%)

13:05
08/21/19
08/21
13:05
08/21/19
13:05
On The Fly
#SocialStocks: New 'Off-Facebook Activity' tool, Argus upgrades Pinterest »

Welcome to…

FB

Facebook

$185.03

1.27 (0.69%)

TWTR

Twitter

$42.65

0.355 (0.84%)

PINS

Pinterest

$36.40

2.05 (5.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

ALXN

Alexion

$113.91

2.49 (2.23%)

13:05
08/21/19
08/21
13:05
08/21/19
13:05
Options
Alexion call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 02

    Oct

  • 19

    Oct

VIOT

Viomi Technology

$9.00

-0.27 (-2.91%)

12:57
08/21/19
08/21
12:57
08/21/19
12:57
Initiation
Viomi Technology initiated at Needham »

Viomi Technology assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

MAS

Masco

$40.58

0.95 (2.40%)

, GWW

Grainger

$276.25

4.29 (1.58%)

12:57
08/21/19
08/21
12:57
08/21/19
12:57
Periodicals
Masco trades higher after Bloomberg report on bidders for cabinet-making unit »

Late in the trading…

MAS

Masco

$40.58

0.95 (2.40%)

GWW

Grainger

$276.25

4.29 (1.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

  • 23

    Oct

PFPT

Proofpoint

$117.13

5.14 (4.59%)

12:55
08/21/19
08/21
12:55
08/21/19
12:55
Conference/Events
Proofpoint participates in a conference call with Wedbush »

Software Analyst Koenig…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 28

    Aug

  • 28

    Aug

  • 05

    Sep

  • 10

    Oct

  • 15

    Oct

  • 13

    Nov

  • 12

    Dec

  • 16

    Dec

BLK

BlackRock

$420.88

2.92 (0.70%)

12:54
08/21/19
08/21
12:54
08/21/19
12:54
Periodicals
BlackRock funds get approval to acquire stake in Cofense, WSJ reports »

The Committee on Foreign…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

GS

Goldman Sachs

$200.90

0.98 (0.49%)

12:52
08/21/19
08/21
12:52
08/21/19
12:52
Periodicals
Goldman Sachs studying sale of Safe-Guard Products unit, Reuters reports »

Goldman Sachs is working…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

JNJ

Johnson & Johnson

$131.60

1.03 (0.79%)

, LLY

Eli Lilly

$111.90

0.94 (0.85%)

12:26
08/21/19
08/21
12:26
08/21/19
12:26
Periodicals
HHS appeals ruling over pharma prices in TV ads, STAT News reports »

The U.S. Department of…

JNJ

Johnson & Johnson

$131.60

1.03 (0.79%)

LLY

Eli Lilly

$111.90

0.94 (0.85%)

MRK

Merck

$87.16

1.5 (1.75%)

PFE

Pfizer

$35.04

0.42 (1.21%)

SNY

Sanofi

$43.35

0.76 (1.78%)

AZN

AstraZeneca

$45.59

0.97 (2.17%)

GSK

GlaxoSmithKline

$40.85

0.59 (1.47%)

NVS

Novartis

$90.50

1.43 (1.61%)

RHHBY

Roche

$0.00

(0.00%)

BMY

Bristol-Myers

$47.65

0.02 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 21

    Aug

  • 26

    Aug

  • 27

    Aug

  • 28

    Aug

  • 02

    Sep

  • 03

    Sep

  • 04

    Sep

  • 06

    Sep

  • 06

    Sep

  • 09

    Sep

  • 09

    Sep

  • 16

    Sep

  • 16

    Sep

  • 19

    Sep

  • 20

    Sep

  • 23

    Sep

  • 25

    Sep

  • 01

    Oct

  • 02

    Oct

  • 15

    Oct

  • 23

    Oct

  • 29

    Oct

  • 04

    Nov

NVRO

Nevro

$84.55

1.57 (1.89%)

12:25
08/21/19
08/21
12:25
08/21/19
12:25
Conference/Events
Nevro participates in a conference call with SVB Leerink »

SVB Leerink holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 26

    Aug

  • 09

    Sep

VG

Vonage

$13.53

0.185 (1.39%)

, FIVN

Five9

$64.11

1.63 (2.61%)

12:25
08/21/19
08/21
12:25
08/21/19
12:25
Conference/Events
Stephens Cloud Infrastructure Analyst to hold Analyst/Industry conference call »

Enterprise & Cloud…

VG

Vonage

$13.53

0.185 (1.39%)

FIVN

Five9

$64.11

1.63 (2.61%)

TWLO

Twilio

$132.21

5.32 (4.19%)

WORK

Slack Technologies

$31.07

0.575 (1.89%)

AMZN

Amazon.com

$1,824.00

21.92 (1.22%)

MSFT

Microsoft

$138.82

1.57 (1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 04

    Sep

  • 04

    Sep

  • 05

    Sep

  • 10

    Sep

  • 27

    Oct

  • 13

    Nov

AAPL

Apple

$213.25

2.9 (1.38%)

, FB

Facebook

$185.05

1.29 (0.70%)

12:21
08/21/19
08/21
12:21
08/21/19
12:21
Periodicals
Trump says relationship better with Apple CEO than other tech execs, CNBC says »

CNBC's Eamon Javers…

AAPL

Apple

$213.25

2.9 (1.38%)

FB

Facebook

$185.05

1.29 (0.70%)

AMZN

Amazon.com

$1,824.53

22.45 (1.25%)

GOOGL

Alphabet Class A

$1,195.80

11.54 (0.97%)

GOOG

Alphabet

$1,195.03

11.6 (0.98%)

TWTR

Twitter

$42.78

0.485 (1.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 21

    Aug

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
08/21/19
08/21
12:17
08/21/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IGLD

Internet Gold

$24.80

-0.75 (-2.94%)

12:16
08/21/19
08/21
12:16
08/21/19
12:16
Hot Stocks
Internet Gold announces receipt of Nasdaq non-compliance notice »

Internet Gold announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$8.32

-0.07 (-0.83%)

12:16
08/21/19
08/21
12:16
08/21/19
12:16
Hot Stocks
NY AG files lawsuit against EPA over GE Hudson River PCB cleanup »

New York Attorney General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 30

    Oct

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
08/21/19
08/21
12:16
08/21/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.